Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis by Shuangjiang Li et al.
RESEARCH ARTICLE Open Access
Clinicopathological and prognostic
significance of mTOR and phosphorylated
mTOR expression in patients with
esophageal squamous cell carcinoma:
a systematic review and meta-analysis
Shuangjiang Li1,3†, Zhiqiang Wang1†, Jian Huang1†, Shan Cheng2, Heng Du1, Guowei Che1* and Yong Peng3*
Abstract
Background: Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase responsible for
regulating ribosomal biogenesis and protein synthesis. Dysregulation of mTOR contributes to tumorigenesis,
angiogenesis, cellular growth and metastasis but its roles in esophageal squamous cell carcinoma (ESCC) are
controversial. Therefore, the objective of this study is to evaluate the prognostic and clinicopathological significance
of mTOR/p-mTOR expression in ESCC.
Methods: Literature retrieval was conducted by searching PubMed, EMBASE and the Web of Science for full-text
papers that met our eligibility criteria. Odds ratio (OR) and hazard ratio (HR) with 95 % confidence interval (CI)
served as the appropriate summarized statistics for assessments of clinicopathological and prognostic significance,
respectively. Cochrane Q-test and I2-statistic were adopted to estimate the heterogeneity level between studies.
Potential publication bias was detected by Begg’s test and Egger’s test.
Results: A total of 915 ESCC patients from nine original articles were included into this meta-analysis. The pooled
analyses suggested that mTOR/p-mTOR expression was significantly correlated with the unfavorable outcomes of
differentiation degree (OR: 2.63; 95 % CI: 1.71–4.05; P = 0.001), tumor invasion (OR: 1.48; 95 % CI: 1.02–2.13; P = 0.037),
TNM stage (OR: 2.25; 95 % CI: 1.05–4.82; P = 0.037) and lymph node metastasis (OR: 1.82; 95 % CI: 1.06–3.11; P = 0.029),
but had no significant relationship to the genders (OR: 0.81; 95 % CI: 0.50–1.32; P = 0.396). Moreover, mTOR/p-mTOR
expression could independently predict the worse overall survival (HR: 2.04; 95 % CI: 1.58–2.62; P < 0.001), disease-free
survival (HR: 2.39; 95 % CI: 1.64–3.49; P < 0.001) and cancer-specific survival (HR: 1.62; 95 % CI: 1.18–2.23; P = 0.003) of
patients with ESCC. Such prognostic value of mTOR was not substantially altered by further subgroup analyses.
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Conclusions: Positive expression of mTOR and p-mTOR was significantly associated with the unfavorable conditions
on the depth of tumor invasion, TNM stage, differentiation degree and lymph node metastasis. mTOR and p-mTOR
could serve as a valuable predictor for the poor prognosis of ESCC. More high-quality worldwide studies performing a
multivariate analysis based on larger sample size are urgently required for further verifying and modifying our findings
in the future.
Keywords: Mammalian target of rapamycin (mTOR), Esophageal squamous cell carcinoma, Prognosis, Systematic
review, Meta-analysis
Background
Esophageal squamous cell carcinoma (ESCC) is one of the
highly aggressive cancers. It has become a worldwide chal-
lenge to human health, particularly to the peoples in
developing countries [1]. According to the latest authori-
tative estimations in China, the incidence of ESCC ranks
the fourth in all cancers, with the rate of 22.14 cases per
100,000 people. Moreover, the mortality of ESCC also
ranks the fourth in all cancers, with a crude rate of 16.77
cases per 100,000 people [2, 3]. The five-year survival rate
of operable ESCC ranges from 10 % to 36 %, suggesting
its current poor prognosis [4, 5]. During the last decade,
advanced surgical techniques, anesthetic techniques and
perioperative managements have dramatically improved
the feasibility and safety of esophagectomy but hardly
benefited the prognosis of ESCC [4]. The possible main
reason may be the detectable regional and distant metas-
tasis in most of the patients with ESCC [6, 7]. The local-
regional recurrence rate after esophagectomy ranges from
20.5 % to 43 %, which can also cause adverse effects on
the survival outcomes of ESCC [8–10].
Given such concerns, identifying a group of novel bio-
markers efficiently promising the prognostic and clinico-
pathological characteristics of ESCC is in urgent need.
In recent years, the phosphatidylinositol 3-kinase/v-akt
murine thymoma viral oncogene homolog 1/mammalian
target of rapamycin pathway (PI3K/Akt/mTOR pathway)
has emerged as one potential candidate on serving as a
therapeutic target of cancers [11]. As a key component
of this signaling pathway, mTOR is also known as
“FK506 binding protein 12-rapamycin associated protein
1” and serves as a serine/threonine protein kinase re-
sponsible for regulating protein synthesis, ribosomal
protein translation and cap-dependent translation [12].
In response to extracellular stimuli, mTOR is activated
by the phosphorylation of Ser2448 through the PI3K/
Akt/mTOR pathway, and it then activates the eukaryotic
translation factor 4E (elF4E) and p70 ribosomal S6 kin-
ase (p70S6 kinase) [12, 13]. mTOR consists of two inde-
pendent functional complexes, mTORC1 and mTORC2,
and the dysregulation of mTOR plays a crucial role in
tumorigenesis, angiogenesis, cellular growth and metas-
tasis [12, 14].
Nowadays, oncologists have increasingly focused on
the potential of mTOR as an anticancer therapeutic tar-
get and evaluated its specific inhibitors in some phase I/
II trials [15–17]. The potential prognostic value of
mTOR and phosphorylated mTOR (p-mTOR) has also
been extensively studied in a variety of cancers, includ-
ing lung cancer [18], gastric cancer [19, 20], breast can-
cer [21], colorectal cancer [22, 23] and urological cancer
[24]. Recently, many clinical reports have attempted to
investigate the roles of mTOR and p-mTOR in ESCC
but some controversial results are not well-interpreted.
A consensus concerning the prognostic value of mTOR/
p-mTOR expression and its relationship to some com-
mon clinicopathological characteristics of ESCC still re-
mains a debate until now.
Limited sample availability in individual studies may
result in negative bias risks on clarifying this pending
issue accurately. Meta-analysis is generally regarded as a
well-established method synthesizing the appropriate
evidence from homogeneous studies to draw global con-
clusions [25–29]. Therefore, we carried out the current
systematic review with meta-analysis to evaluate the
prognostic and clinicopathological significance of mTOR/
p-mTOR expression in patients with ESCC.
Methods
Protocol
No protocol had been previously published for this re-
view. Our study was conducted in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement (PRISMA 2009
Checklist not shown) [30].
Eligibility criteria
The following inclusion and exclusion criteria were
established to determine the appropriate studies in-
cluded into our meta-analysis.
Inclusion criteria
For the study designs, a quantitatively comparative ana-
lysis performed among the consecutive patients could be
considered of eligibility.
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For the participants, the target disease was ESCC, in-
cluding all the clinical stages required for surgical proce-
dures, neo-adjuvant and adjuvant therapies. No
limitation was imposed for ages or genders.
For the interventions, the positive expression of
mTOR/p-mTOR should be independently analyzed in-
stead of collaborating with other biomarkers. Immuno-
histochemistry (IHC) was considered as the only eligible
experimental method for mTOR/p-mTOR staining in
ESCC specimens.
For the outcome measures, studies reporting any one
of the following data in their results could be included
into this meta-analysis. First, sufficient demographics or
statistics should be available for the estimate of odds ra-
tio (OR), relative risk (RR) and hazard ratio (HR) to de-
termine the relationship between mTOR/p-mTOR
expression and clinicopathological characteristics of
ESCC. Second, any statistic evaluating the prognostic
significance of mTOR/p-mTOR expression in ESCC was
directly reported. Third, if no statistical result was con-
ducted, the survival data with log-rank P value and
Kaplan-Meier survival curves would also be considered
of eligibility.
For the follow-ups, the key endpoints involved the
overall survival (OS), disease-free survival (DFS) and
cancer-specific survival (CSS). The follow-up period
should be lasting for at least one year.
In addition, the most recent studies should be finally
included if they were performed on overlapping patients.
Only full-text papers published in peer-reviewed journals
were finally included.
Exclusion criteria
Firstly, the following articles should be immediately ex-
cluded because of their irrelevant styles, including case
reports, reviews, animal experiments, conference ab-
stracts and letters. Secondly, a comparison of mTOR/p-
mTOR expression between carcinomatous tissues and
normal tissues was not considered. Thirdly, any continu-
ous variable would not be included into quantitative syn-
thesis. Fourth, positive expression of mTOR/p-mTOR
was not stained by IHC.
Search strategy
A comprehensive literature search for this meta-analysis
was conducted between May 16, 2016 and May 21,
2016. No language or publication date restriction was
imposed during the retrieval.
Two of our researchers were assigned to search three
universal electronic databases, including PubMed,
EMBASE (via Ovid interface) and the Web of Science
(via campus network of Sichuan University), to identify
the eligible studies published up to May 16, 2016. Con-
sulting similar meta-analyses addressing on the
prognostic value of biomarkers [25, 26, 28], we com-
bined the following six key words with Boolean Opera-
tors (“AND” and “OR”), including four “esophageal
cancer” terms and two “mTOR” terms, to formulate two
search strings in each selected database. These key
words are listed as follows:
(I) Esophageal cancer terms: “esophageal cancer”,
“esophageal carcinoma”, “esophageal neoplasm” and
“esophageal malignancy”;
(II)mTOR terms: “mammalian target of rapamycin” and
“mTOR”.
Complete search details are outlined in the Additional
file 1. Meanwhile, a manual search for the reference lists
of retried studies was also conducted to identify any pos-
sibly included study with no duplication.
Data collection
Process
We designed a Microsoft Office Excel spreadsheet to ex-
tract the basic information from included studies. The
data collection process was developed by two of our re-
searchers and cross-checked by another one reviewer.
Data items
The following details were collected from each included
study:
(i) Publication data including authors, publication
years, populations and languages;
(ii)Experimental data including study design, study
period, investigating categories, experimental
materials, detecting methods, IHC techniques
(antibodies and dilution), positive-staining sites, cut-
off values, endpoints and follow-up periods;
(iii)Demographic data including total sample size,
genders, ages, the number of patients with positive
and negative expression of mTOR/p-mTOR, the
number of patients treated with neo-adjuvant induc-
tion therapy (NIT), and TNM stages of ESCC.
(iv) Statistical data including the outcome statistics with
their extractions, and the corresponding statistical
analysis methods (including univariate analysis and
multivariate analysis).
Risk of bias in individual studies
Newcastle-Ottawa Scale (NOS) was employed to quan-
tify the quality levels of non-randomized studies [31].
Three perspectives including selection, comparability
and exposure were considered for a semi-quantitative
estimation. The “star system” with a maximum of 9 stars
was used to grade all the included studies. We regarded
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8–9 stars as good quality, 6–7 stars as fair quality, and
lower than 6 stars as poor quality.
Statistical analysis
All of the following steps of statistical analyses were ac-
complished by STATA 12.0 (STATA Corporation, Col-
lege Station, TX, USA).
Summary measures
For the assessments of relationships between mTOR/p-
mTOR expression and clinicopathological features of
ESCC, OR with 95 % CI served as the appropriate sum-
marized statistics. These OR outcomes were generally
extrapolated from the reported demographic data [32]. If
the relevant HR or RR was reported, we could immedi-
ately incorporate it into the meta-analysis.
For the assessments of prognostic value of mTOR/p-
mTOR expression in ESCC, we determined the HR with
95 % CI to be the summarized estimates because HR
was the only appropriate statistic compatible for both
censoring and time-to-events [33]. It would be our first
priority to incorporate the HR outcomes derived from
multivariate analysis into quantitative synthesis because
multivariate analysis using logistic regression or Cox
proportional hazards model was generally used to elim-
inate the bias risks from other confounding factors in
observational studies. If no multivariate statistic was
available, we could extract the HR with 95 % CI from
the reported survival data with log-rank P value accord-
ing to a practical method described by Tierney et al.




Total observed events  Analyzed research Analyzed controlp
Analyzed researchþ Analyzed controlð Þ
 Z score f or P value=2ð Þ
V ¼ Total observed events  Analyzed research Analyzed control
Analyzed researchþ Analyzed controlð Þ2
HR ¼ Exp −O−E
V
 
Where O-E is the log-rank Observed minus Expected
events and V is the log-rank Variance [34].
Synthesis of results
Both the Cochrane Q-test and I2-statistic were adopted
for the estimate of heterogeneity level within this meta-
analysis. Fine heterogeneity was defined by I2 < 50 % and
p > 0.1, and a standard fixed-effect model test (Mantel–
Haenszel method) would be required for quantitative
synthesis. Otherwise, a random-effect model test (DerSi-
monian and Laird method) would be applied when a
prominent heterogeneity was revealed by I2 ≥ 50 % or
p ≤ 0.1 [35].
Additional analysis
Sensitivity analysis was conducted to examine the stabil-
ity of all summarized outcomes, in which the impact of
each study on the overall estimates could be detected by
omitting the individual study sequentially. The robust-
ness of our meta-analysis would be confirmed if there
was no substantial variation between the adjusted pooled
estimates and primary pooled estimates [36].
Publication bias
Both the Begg’s test and Egger’s test were collabo-
rated to evaluate the potential publication bias be-
tween studies. On the one hand, the presence of bias
was suggested by the visual symmetry of Begg’s fun-
nel plot, in which log ORs or log HRs were plotted
against their corresponding standard errors [37]. On
the other hand, its significance was also suggested by
Egger’s p value. Finally, a significant bias would be re-
vealed by either visual asymmetry of Begg’s funnel
plot or Egger’s p value < 0.05.
Results
Study selection
The major procedures for literature retrieval was con-
cisely summarized as a PRISMA diagram (Fig. 1). A total
of 521 items of publications were primarily identified
from the electronic databases, including 155 citations in
PubMed, 119 citations in EMBASE and 247 citations in
the Web of Science. In addition, a manual search of the
reference lists also yielded two potentially relevant stud-
ies. After excluding 353 duplicates, the remaining 170
works entered into the initial filtration based on screen-
ing their titles and abstracts. Then, 107 of them were
immediately excluded from the further filtration because
of their irrelevant styles. By reading through the re-
trieved papers, 54 articles focusing on irrelevant issues
were further excluded and the remaining nine articles
were considered of possible eligibility. Finally, these nine
studies were judged to meet all of the eligibility criteria
and included into this meta-analysis [38–46].
Study characteristics
Baseline characteristics for nine eligible articles are gen-
eralized in Tables 1 and 2.
Study designs
There were 14 included studies reported from nine eli-
gible articles, including eight studies focusing on the re-
lationship between mTOR/p-mTOR expression and
clinicopathological characteristics of ESCC and six stud-
ies analyzing the prognostic value of mTOR/p-mTOR
expression in ESCC. All of these 14 included studies be-
long to retrospective observational studies [38–46], and
they were published between 2008 and 2015 (Tables 1
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and 2). Only one of them was finished in Chinese [39]
and the others were published in English [38, 40–46].
Participants
This meta-analysis involved a total of 915 ESCC cases,
including 502 Chinese patients from China mainland
and Taiwan region (ratio = 54.9 %) [39, 40, 42, 44–46],
165 patients from Korea (ratio = 18.0 %) [43], 143 pa-
tients from Japan (ratio = 15.6 %) [41] and 105 patients
from Netherland (ratio = 11.5 %) [38]. All of these pa-
tients were consecutively enrolled from 1989 to 2012.
The sample size ranged from 34 to 165 across the in-
cluded studies (Tables 1 and 2). Among these patients,
there were 131 patients received NIT before esophagec-
tomy and the remaining 784 patients underwent
esophagectomy alone. In addition, the details for gender
proportions, mean ages and clinical stages in each in-
cluded study are also outlined in Tables 1 and 2.
Interventions
As for experimental materials, IHC was commonly used
for staining mTOR/p-mTOR in paraffin-embedded spec-
imens [38–46]. The cut-off definitions for positive ex-
pression of mTOR/p-mTOR and their corresponding
positive sites varied across the current studies but over-
lapped for some common evaluations (Tables 1 and 2).
There was also a substantial difference in antibody use
(Ser2448 or Rabbit anti-mTOR antibody) and the corre-
sponding dilution (ranged from 1:200 to 1:50) between
studies (Tables 1 and 2). Given above reviews, mTOR/p-
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram for literature retrieval. ESCC, esophageal squamous cell
carcinoma; mTOR, mammalian target of rapamycin; p-mTOR, phosphorylated mammalian target of rapamycin
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Table 1 Baseline characteristics of included studies











CP features Prognosis Total PE NE
Boone et al. (2008) [38] English Netherland ROS 1989–2006 7 ✓ ✗ 105 26 79 62.0 56/49 None I-IV
Chen et al. (2010) [39] Chinese China mainland ROS 2006–2007 7 ✓ ✗ 62 33 29 NI NI None NI
Chuang et al. (2015) [40] English Taiwan ROS NI 8 ✓ ✓ 75 39 36 57.0 72/3 54/21 I-IV
Hirashima et al. (2010) [41] English Japan ROS 1996–2006 9 ✓ ✓ 143 71 72 63.8 126/17 None I-III
Hou et al. (2014) [42] English China mainland ROS NI 7 ✓ ✗ 35 22 13 61.3 16/19 None I-IV
Kim et al. (2013) [43] English Korea ROS 1995–2008 8 ✓ ✓ 165 74 91 NI 159/6 None I-IV
Li et al. (2012) [44] English Taiwan ROS 1999–2009 9 ✗ ✓ 77 44 33 52.0 75/2 All received I-III
Li et al. (2015) [45] English Taiwan ROS NI 8 ✓ ✓ 105 59 46 54.0 103/2 None I-IV
Lu et al. (2015) [46] English China mainland ROS 2010–2012 8 ✓ ✓ 148 94 54 59.0 114/34 None I-III
CP clinicopathological, CSS cancer-specific survival, DDE demographic data extrapolated, DFS disease-free survival, HR hazard ratio, IHC immunohistochemistry, M multivariate, NE negative expression, NI no information,










Table 2 Baseline characteristics of included studies
Authors (Year) Materials Detection Antibody Dilution Positive site Cut-off value Estimates Extractions Analysis Endpoints Follow-up
Boone et al. (2008) [38] Paraffin-embedded tissue IHC Ser2448 1:50 Cytoplasm 20 % staining OR DDE U –––– ––––
Chen et al. (2010) [39] Paraffin-embedded tissue IHC Rabbit anti-mTOR 1:100 Cytoplasm 10 % staining OR DDE U –––– ––––
Chuang et al. (2015) [40] Paraffin-embedded tissue IHC Rabbit anti-mTOR 1:100 NI Median H-score OR, HR DDE U OS 120 months
Hirashima et al. (2010) [41] Paraffin-embedded tissue IHC Ser2448 1:50 Cytoplasm 10 % staining OR, HR Reported, DDE U & M OS, CSS 133 months
Hou et al. (2014) [42] Paraffin-embedded tissue IHC Rabbit anti-mTOR 1:200 Cytoplasm 10 % staining OR DDE U –––– ––––
Kim et al. (2013) [43] Paraffin-embedded tissue IHC Ser2448 1:100 NI 5 % staining OR, HR Reported, DDE U & M OS, CSS 120 months
Li et al. (2012) [44] Paraffin-embedded tissue IHC Ser2448 1:50 Cytoplasm 10 % staining HR Reported M OS, DFS 120 months
Li et al. (2015) [45] Paraffin-embedded tissue IHC Ser2448 1:50 Cytoplasm 10 % staining OR, HR DDE U OS, DFS 146 months
Lu et al. (2015) [46] Paraffin-embedded tissue IHC Rabbit anti-mTOR 1:100 Cytoplasm 25 % staining OR, HR Reported, DDE U & M OS, DFS 36 months
CP clinicopathological, CSS cancer-specific survival, DDE demographic data extrapolated, DFS disease-free survival, HR hazard ratio, IHC immunohistochemistry, M multivariate, NE negative expression, NI no information,










mTOR expression was detected in 462 patients, with the
positive ratio of 50.5 %.
Outcome measures
To estimate the relationship between mTOR/p-mTOR
expression and clinicopathological characteristics of
ESCC, none of the eight relevant studies provided any
statistical data derived from multivariate analysis but re-
ported the demographic details [38–43, 45, 46]. The OR
statistics incorporated into quantitative synthesis were
commonly extrapolated from these demographics, which
were based on univariate analysis (Tables 1 and 2).
To evaluate the prognostic significance of mTOR/p-
mTOR expression in ESCC, seven multivariate statistics
were directly reported from six included studies, includ-
ing four HR statistics for OS [41, 43, 44, 46], two HR
statistics for DFS [44, 46] and one HR statistic for CSS
[43]. Besides, the additional four HR statistics could be
extrapolated from the survival data based on univariate
analysis, including two for OS [40, 45], one for CSS [41]
and one for DFS [45]. In addition, the maximum follow-
up period ranged from 36 to 146 months between stud-
ies (Tables 1 and 2).
Risk of bias within studies
The quality level of all the included studies was graded
by a NOS score, then listed by the number of stars (see
the Additional file 2). Finally, these studies had a mean
score of 7.8 (ranged from 7 to 9), indicating a fairly good
quality level.
Synthesis of results
Positive mTOR/p-mTOR expression and clinicopathological
characteristics of ESCC
In our meta-analysis, common clinicopathological vari-
ables of ESCC involved the gender, depth of tumor inva-
sion (T factor), differentiation degree, TNM stage (III/IV
vs I/II) and lymph node metastasis (LNM). Their pooled
analyses showed that mTOR/p-mTOR expression was
significantly associated with the worse outcomes for dif-
ferentiation degree (OR: 2.63; 95 % CI: 1.71–4.05; P =
0.001; I2 = 29.3 %, p = 0.216; Table 3 and Fig. 2a), tumor
invasion (OR: 1.48; 95 % CI: 1.02–2.13; P = 0.037; I2 =
0.0 %, p = 0.546; Table 3 and Fig. 2b), TNM stage (OR:
2.25; 95 % CI: 1.05–4.82; P = 0.037; I2 = 82.9 %, p < 0.001;
Table 3 and Fig. 2c) and LNM (OR: 1.82; 95 % CI: 1.06–
3.11; P = 0.029; I2 = 69.2 %, p = 0.002; Table 3 and
Fig. 2d). However, mTOR/p-mTOR expression seemed
to have no significant relationship to the genders of pa-
tients with ESCC (OR: 0.81; 95 % CI: 0.50–1.32; P =
0.396; I2 = 0.0 %, p = 0.447; Table 3 and Fig. 2e).
Prognostic roles of mTOR/p-mTOR expression in patients
with ESCC
We performed a pooled analysis based on six in-
cluded studies to evaluate the relationship between
mTOR/p-mTOR expression and OS of ESCC patients
[40, 41, 43–46]. The summarized estimates suggested
that mTOR/p-mTOR expression was significantly corre-
lated with the worse OS in patients with ESCC (HR: 2.04;
95 % CI: 1.58–2.62; P < 0.001; Table 4 and Fig. 3), without
any heterogeneity (I2 = 0.0 %, p = 0.493).
Similarly, such significant relationships between mTOR/
p-mTOR expression and unfavorable prognosis of ESCC
were still statistically reliable within the pooled analyses of
three studies for DFS outcomes (HR: 2.39; 95 % CI:
1.64–3.49; P < 0.001; I2 = 0.0 %, p = 0.970; Table 4 and
Fig. 3) [44–46] and two studies for CSS outcomes
(HR: 1.62; 95 % CI: 1.18–2.23; P = 0.003; I2 = 0.0 %, p =
0.853; Table 4 and Fig. 3) [41, 43]. All of the above inte-
grated estimates indicated a strong predictive value of
mTOR/p-mTOR expression for poor prognosis of ESCC.
Subgroup analyses on the prognostic value of mTOR/p-
mTOR expression for OS in patients with ESCC
To further evaluate the prognostic significance of mTOR
and p-mTOR in detail, all of six included studies ad-
dressing on the relationship between mTOR/p-mTOR
expression and OS of ESCC cases were stratified into
several subgroups according to the statistical analysis
methods, cut-off values, follow-up periods and positive-
staining sites [40, 41, 43–46].
A subgroup analysis was conducted in each of above
subgroups. According to the pooled HR statistics, we
found that the association between mTOR/p-mTOR ex-
pression and worse OS of ESCC still remained statistically
prominent in all of the subgroups stratified by statistical
analysis methods (multivariate data, HR: 2.07; 95 % CI:
1.56–2.75; P < 0.001; univariate data, HR: 1.92; 95 % CI:
1.11–3.29; P = 0.019; Table 5 and Fig. 4a), cut-off values
(10 % staining, HR: 2.58; 95 % CI: 1.79–3.71; P < 0.001;
non-10 % staining, HR: 1.64; 95 % CI: 1.16–2.33; P =
0.005; Table 5 and Fig. 4b), follow-up periods (≥5-year OS,
HR: 2.04; 95 % CI: 1.54–2.69; P < 0.001; < 5-year OS, HR:
2.03; 95 % CI: 1.12–3.70; P = 0.020; Table 5 and Fig. 4c)
and positive-staining sites (cytoplasmic staining, HR: 2.42;
95 % CI: 1.77–3.30; P < 0.001; Table 5 and Fig. 4d).
Sensitivity analysis
We conducted a sensitivity analysis to access the stabil-
ity of three summarized HR outcomes revealing the
prognostic value of mTOR/p-mTOR expression for OS,
DFS and CSS in patients with ESCC. As Fig. 5a-c
showed, no substantial variation was finally identified
between the adjusted pooled HR and primary pooled HR
by omitting the individual study sequentially. The strong
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Table 3 Meta-analysis of relationships between mTOR/p-mTOR expression and clinicopathological characteristics of ESCC
Clinicopathological characteristics N No. samples Heterogeneity (I2, p) Model OR with 95 % CI P
value
Publication bias Conclusion
Total PE NE Begg (p) Egger (p)
Differentiation (G3 vs G1/G2) 6 568 285 283 I2 = 29.3 %, p = 0.216 Fixed 2.634 (1.714–4.047) 0.001 0.283 0.456 Significant
Depth of tumor invasion (T3/T4 vs T1/T2) 6 568 318 250 I2 = 0.0 %, p = 0.546 Fixed 1.477 (1.024–2.132) 0.037 0.452 0.355 Significant
TNM stage (III/IV vs I/II) 7 776 385 391 I2 = 82.9 %, p < 0.001 Random 2.248 (1.048–4.823) 0.037 0.087 0.216 Significant
Lymph node metastasis (Yes vs No) 8 838 418 420 I2 = 69.2 %, p = 0.002 Random 1.816 (1.062–3.105) 0.029 0.754 0.626 Significant
Gender (Male vs Female) 6 741 363 378 I2 = 0.0 %, p = 0.447 Fixed 0.811 (0.500–1.316) 0.396 0.371 0.273 Not significant
CI confidence interval, ESCC esophageal squamous cell carcinoma, mTOR Mammalian Target of Rapamycin, N reference count, NE negative expression, OR odds ratio, PE positive expression, p-mTOR Phosphorylated










Table 4 Meta-analysis of prognostic roles of mTOR/p-mTOR expression in patients with ESCC
Endpoint event N No. samples Heterogeneity (I2, p) Model HR with 95 % CI P value Publication bias Conclusion
Total PE NE Begg (p) Egger (p)
Overall survival 6 713 381 332 I2 = 0.0 %, p = 0.493 Fixed 2.036 (1.582–2.620) <0.001 1.0 0.663 Significant
Disease-free survival 3 330 197 133 I2 = 0.0 %, p = 0.970 Fixed 2.390 (1.637–3.490) <0.001 1.0 0.941 Significant
Cancer-specific survival 2 308 145 163 I2 = 0.0 %, p = 0.853 Fixed 1.620 (1.179–2.229) 0.003 1.0 NI Significant
CI confidence interval, ESCC esophageal squamous cell carcinoma, HR hazard ratio, mTOR Mammalian Target of Rapamycin, N reference count, NE negative
expression, NI no information, PE positive expression, p-mTOR Phosphorylated Mammalian Target of Rapamycin
Fig. 2 Meta-analysis on the relationship between mTOR/p-mTOR expression and clinicopathological characteristics of ESCC, including (a)
differentiation degree, (b) tumor invasion, (c) TNM stage, (d) LNM and (e) genders. CI, confidence interval; ESCC, esophageal squamous cell carcinoma;
LNM, lymph node metastasis; mTOR, mammalian target of rapamycin; p-mTOR, phosphorylated mammalian target of rapamycin; OR, odds ratio
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robustness of prognostic significance of mTOR/p-mTOR
expression in ESCC was thus confirmed.
Publication bias
For assessments of publication bias, both the Begg’s p
value and Egger’s p value are listed in Tables 2 and 3
(Begg’s funnel plots not shown). By estimating the corre-
sponding p value, there was no evidence for significant
publication bias detected by either Begg’s test or Egger’s
test across all the included studies.
Discussion
To the best of our knowledge, this is the first meta-
analysis to demonstrate the prognostic significance of
mTOR/p-mTOR expression and its relationship to the
clinicopathological characteristics of ESCC. Our meta-
Fig. 3 Meta-analysis on the prognostic significance of mTOR/p-mTOR expression for OS, DFS and CSS in patients with ESCC. CI, confidence
interval; CSS, cancer-specific survival; DFS, disease-free survival; ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; mTOR, mammalian
target of rapamycin; p-mTOR, phosphorylated mammalian target of rapamycin; OS, overall survival
Table 5 Subgroup analyses for the relationship between mTOR/p-mTOR expression and OS of patients with ESCC
Subgroups N No. samples Heterogeneity (I2, p) Model HR with 95 % CI P value Conclusion
Total PE NE
Subgroups stratified by statistical analysis
Multivariate analysis 4 533 283 250 I2 = 26.0 %, p = 0.255 Fixed 2.071 (1.557–2.753) <0.001 Significant
Univariate analysis 2 180 98 82 I2 = 0.0 %, p = 0.592 Fixed 1.915 (1.114–3.292) 0.019 Significant
Subgroups stratified by cut-off values
10 % staining 3 325 174 151 I2 = 0.0 %, p = 0.731 Fixed 2.577 (1.788–3.714) <0.001 Significant
Non-10 % staining 3 388 207 181 I2 = 0.0 %, p = 0.694 Fixed 1.644 (1.160–2.328) 0.005 Significant
Subgroups stratified by follow-up periods
≥ 5-year OS 5 565 287 278 I2 = 9.2 %, p = 0.354 Fixed 2.037 (1.542–2.689) <0.001 Significant
< 5-year OS 1 148 94 54 –––– –––– 2.033 (1.117–3.701) 0.020 Significant
Subgroups stratified by positive-staining sites
Cytoplasm 4 473 268 205 I2 = 0.0 %, p = 0.785 Fixed 2.416 (1.769–3.301) <0.001 Significant
Nucleus or membrane Given up because of the scarcity of available data
CI confidence interval, ESCC esophageal squamous cell carcinoma, HR hazard ratio, mTOR Mammalian Target of Rapamycin, N reference count, NE negative
expression, OS overall survival, PE positive expression, p-mTOR Phosphorylated Mammalian Target of Rapamycin
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Fig. 4 Subgroup analyses on the prognostic value of mTOR/p-mTOR expression for OS in subgroups of ESCC patients stratified by (a) statistical
analysis, (b) cut-off values, (c) follow-up periods and (d) positive-staining sites. CI, confidence interval; ESCC, esophageal squamous cell carcinoma;
HR, hazard ratio; mTOR, mammalian target of rapamycin; p-mTOR, phosphorylated mammalian target of rapamycin; OS, overall survival
Fig. 5 Sensitivity analysis on the prognostic value of mTOR/p-mTOR expression for (a) OS, (b) DFS and (c) CSS in patients with ESCC. CI,
confidence interval; CSS, cancer-specific survival; DFS, disease-free survival; ESCC, esophageal squamous cell carcinoma; mTOR, mammalian target
of rapamycin; p-mTOR, phosphorylated mammalian target of rapamycin; OS, overall survival
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analysis identified that positive expression of mTOR/p-
mTOR was significantly correlated with the worse
conditions on differentiation degree, depth of tumor in-
vasion, LNM and TNM stage of ESCC but had no rela-
tionship to the genders. Remarkably, mTOR/p-mTOR
expression was also significantly associated with the
worse OS, DFS and CSS in patients with ESCC. Further
subgroup analyses suggested that such significant rela-
tionships between mTOR/p-mTOR expression and poor
OS of ESCC patients still remained statistically reliable
in all of the subgroups stratified by statistical analysis
methods, cut-off values, follow-up periods and positive-
staining sites. All of these pooled analyses indicated that
mTOR/p-mTOR could be a strong predictor for the
poor prognosis of ESCC. Their stabilities were further
confirmed by sensitivity analysis and no publication bias
was detected across the current studies.
Summary of evidence
In 1991, mTOR was firstly discovered as a mammalian
homolog of the target of rapamycin (TOR) proteins in
yeast mutants [47]. TOR is generally regarded as a target
of the macrolide fungicide rapamycin according to the
growth resistance of these mutants to rapamycin, and
mTOR is the structurally and functionally conserved
mammalian counterpart [47, 48]. Because the C-
terminus of mTOR shares substantial homology to the
catalytic domain of P13K, mTOR belongs to the P13K
protein kinase family and is with a molecular weight of
289 kDa [49]. To date, the mTOR gene has frequently
been examined in every eukaryote genome investigation.
It is commonly recognized that mTOR encompasses
two distant functional protein complexes in the organ-
ism, mTORC1 and mTORC2 [14]. mTORC1 consists of
mTOR, Raptor, mLST8, and two negative regulators,
PRAS40 and DEPTOR. Meanwhile, mTORC2 contains
mTOR, Rictor, mLST8, mSin1, Hsp70 and DEPTOR
[11]. There is a huge difference in their sensitivities to
the macrolide fungicide rapamycin. Recent studies sug-
gest that the rapamycin-inhibition properties of mTOR
mainly depends on the activation of mTORC1. The pri-
mary procedures of ribosomal biogenesis and protein
synthesis are regulated by mTORC1 through the phos-
phorylation and activation of Ser2448 [50]. On the con-
trary, mTORC2 is deemed resistant to rapamycin.
However, new evidence indicates that long-term treat-
ment with rapamycin can disrupt the original mTORC2
assembly and sequester the newly synthesized mTOR
molecules [51].
The mTOR signaling pathways strongly correlate with
growth factors, nutrients and the energy availability
underlying cell survival, growth, proliferation and death.
Remarkably, mTOR acts as a “master switch” of further
cellular catabolism and anabolism. In the classical
upstream PI3K/Akt/mTOR pathway, stimulation of class
I P13K activates its downstream effector AKT, and then
leads to the phosphorylation of Ser2448 which plays a
key role in activating the mTOR (p-mTOR) [52, 53].
Moreover, mTOR can be down-regulated through an-
other upstream signaling pathway, the liver kinase B1/
AMP-activated protein kinase/mTOR (LKB1/AMPK/
mTOR) pathway. The anti-oncogene LKB1 directly
phosphorylates the activation loop and increases the ac-
tivity of AMPK kinase [54]. Activated AMPK has an ex-
quisite sensitivity to very subtle changes in intracellular
AMP levels and can directly inhibit the mTOR signals
under energy stress [50, 55]. In the downstream mTOR
signaling pathways, p-mTOR can improve the transla-
tion efficiency of 5’-TOR mRNA and accelerate protein
synthesis by phosphorylating its downstream receptors
during the translation process, such as elF4E and p70S6
kinase [56]. Thus, mTOR pathways can further regulate
some physiological and pathological events through the
activation and phosphorylation of various exogenous
stimuli and essential signaling pathways [11].
On the basis of above molecular mechanisms, mTOR/
p-mTOR expression has increasingly been identified to
be involved in some cancers [57]. Aberrant activation of
mTOR pathway induced by the loss of tumor suppres-
sors and oncogene stimulation can significantly promote
tumor growth, angiogenesis and metastasis [58]. The
mutations in mTOR gene confer a probability of consti-
tutive activation of mTOR signaling pathways, even
under nutrient starvation conditions [59]. Other signal-
ing components of the upstream and downstream
mTOR pathways are also frequently altered during pro-
liferation dysregulation, which is associated with poor
cancer prognosis [50]. In addition, activated mTOR sig-
nals can also contribute to the development of several
syndromes with benign tumors composed of architectur-
ally disorganized but well-differentiated cells, such as
Cowden’s syndrome, Peutz-Jeghers syndrome and tuber-
ous sclerosis. These syndromes may further develop to
the malignancy [60].
In recent years, numbers of clinical evidence have inves-
tigated the prognostic value of positive mTOR/p-mTOR
expression in many common cancers, including ESCC. By
integrating the outcome data from all the currently avail-
able studies, our meta-analysis showed that mTOR could
be a strong biomarker for poor prognosis of ESCC, be-
cause that a prognostic marker would be considered of
high predictive value for the negative prognosis if its HR
value was larger than 2 [25, 28]. Remarkably, further sub-
group analyses indicated that such relationships between
mTOR/p-mTOR expression and worse survival of ESCC
were not substantially altered by different endpoints, cut-
off values and follow-up periods. Besides, we also had an
attempt to estimate the relationship between mTOR/p-
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mTOR expression and several major clinicopathological
of ESCC. Positive expression of mTOR/p-mTOR was
found to be significantly associated with the worse condi-
tions on tumor invasion, differentiation degree, TNM
stage and LNM, all of which were critical factors resulting
in the negative prognosis of ESCC. We speculated that the
clinicopathological significance of mTOR/p-mTOR ex-
pression might be able to interpret its prognostic roles in
ESCC to some extent.
Another issue worth to be discussed was the correl-
ation between mTOR/p-mTOR expression and NIT sen-
sitivity to ESCC. In this meta-analysis, only one study
conducted by Li et al. [44] reported the survival data of
77 surgical patients followed by NIT. According to the
multivariate analysis, p-mTOR was found to be inde-
pendently associated with the response to NIT and prog-
nosis of ESCC patients treated with NIT. Their
laboratorial evidence also indicated that inhibition of
mTOR could sensitize ESCC cell lines to chemotherapy,
suggesting that the mTOR inhibitor could enhance the
efficacy of NIT. However, as the researchers suggested,
the validity of these findings might be limited by rela-
tively short follow-up periods and small sample availabil-
ity. Anyway, the significance of mTOR activation in NIT
sensitivity and its impact on the prognosis of ESCC
should be further evaluated by more large-scale studies
with prolonged follow-up periods in the future.
Limitations
We noticed that the following five fields of bias risks
might cause adverse effects on the validity of pooled es-
timates within our meta-analysis. These major limita-
tions should be acknowledged and seriously considered
in the clinical practices.
First of all, our pooled analyses on the prognostic sig-
nificance of mTOR/p-mTOR expression and its relation-
ship to clinicopathological characteristics of ESCC were
based on only 915 ESCC cases enrolled from 14 retro-
spective observational studies [38–46]. It is generally
proposed that multivariate analysis using Cox propor-
tional hazards model or logistic regression is usually
adopted to eliminate the potential bias risks from other
confounding factors in observational studies [25–27, 29].
In this meta-analysis, no multivariate OR statistic was
reported to assess the relationship between mTOR/p-
mTOR expression and clinicopathological features of
ESCC. Furthermore, there were two HR statistics extrap-
olated from the published survival details based on uni-
variate analysis and incorporated into the prognostic
assessments. Thus, we doubted that the accuracy of
overall pooled estimates for OS, DFS and CSS might be
slightly attenuated by some insufficiently eliminated con-
founders that could affect the prognosis of ESCC, such
as TNM stages, tumor invasion, differentiation degree
and LNM. These possible parameters might interfere the
identification of actual roles of mTOR and p-mTOR in
ESCC, although a strong linkage between mTOR/p-
mTOR expression and their unfavorable conditions had
been revealed by our meta-analysis. Therefore, the valid-
ity and accuracy of all the summarized outcomes should
be further verified and modified in the future multivari-
ate analyses without any bias risk from other confound-
ing factors.
Second, there is a substantial variation in the propor-
tion of positive samples across the included studies,
which ranged from 24.8 % to as high as 62.9 % [38, 42].
We suspected that the huge heterogeneity existed within
the cut-off values for positive expression of mTOR/p-
mTOR might be the most compelling explanations for
this finding. Because cut-off definitions for positive
mTOR expression varied notably from 5 % staining to
25 % staining of cancer cells between studies, an un-
avoidable deviation originated from heterogeneous cri-
teria of evaluation could negatively affect the validity of
pooled estimates. Another one major reason worthy of
our attentions was the different antibodies and dilutions
used in the experimental IHC techniques (Tables 1 and 2).
A scarcity of unified IHC methods could also cause ad-
verse effects on the homogeneity level of included studies
[25]. Given such concerns, all of above aspects of limita-
tions must be judiciously evaluated when interpreting our
summarized outcomes correctly.
Third, we noticed that the study years of included
studies ranged from 1989 to 2012, and the ESCC staging
criteria had some changes during this time-frame of
nearly 25 years. The pathological stages of ESCC were
determined according to the latest seventh edition of
American Joint Committee on Cancer (AJCC) staging
system in five eligible articles [40, 43–46]. However, the
earliest study conducted by Boone et al. [38] was pub-
lished in 2008 and staged the ESCC according to the
previous sixth edition AJCC criteria. Compared to the
sixth edition of AJCC staging system, the updated sev-
enth criteria has a great improvement in the refinement
of LNM classification and also enrich the traditional
TNM staging by adding evaluations for histological sub-
types, differentiation degree and tumor locations [61].
Therefore, the variations of ESCC staging could be one
important source of bias when synthesizing the current
evidence in our meta-analysis.
Fourth, it has been generally recognized that studies
reporting beneficial intervention effects or a larger effect
size are more likely to be published, while an equal
amount of data towards the other directions may remain
unpublished [29]. This phenomenon suggests that we
cannot avoid the potential publication bias between
studies included into a meta-analysis. However, less than
10 included studies can lead to a large decline on the
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efficacy of publication bias tests, resulting in the poten-
tially misleading evidence for publication bias [25–29].
As for our meta-analysis, no more than 10 studies were
included into each analysis for either clinicopathological
characteristics or prognosis of ESCC. We suspected that
potential publication bias might still exist across the in-
cluded studies, although no significant evidence could
be validly detected up to now.
Finally, we gave up to stratify the enrolled patients ac-
cording to their nations and perform a subgroup analysis
to further evaluate the potential ethnic differences in
prognostic roles of mTOR/p-mTOR expression for
ESCC, because all of the included studies were con-
ducted among East-Asian populations [40, 41, 43–46].
No study assessing the prognostic value of mTOR/
p-mTOR in Western ESCC patients was identified
but only one study reported by Boone et al. [38] analyzed
the relationship between mTOR/p-mTOR expression and
clinicopathological features of 105 ESCC patients from
the Netherlands. In general, ESCC occurs much more fre-
quently in patients considered with a low socioeconomic
status and living conditions because they receive little
medical treatment and health care [62]. That may be a
reason for the scarcity of available evidence from devel-
oped Western countries. Recently, a large genome-wide
association study on ESCC has identified several suscepti-
bility genes in Chinese populations [63]. However, no gen-
etic susceptibility to ESCC has been identified among
Caucasians until now. The potential effects of susceptibil-
ity genes on the activity of mTOR remain unclear. There-
fore, our findings should be judiciously considered in the
clinical settings of Western nations. More well-designed
clinical reports were urgently required to clarify the prog-
nostic value of mTOR in Caucasian patients with ESCC.
Conclusions
In conclusion, our meta-analysis demonstrated that the
positive expression of mTOR and p-mTOR was signifi-
cantly correlated with the unfavorable outcomes on the
depth of tumor invasion, TNM stage, differentiation de-
gree and LNM. Furthermore, mTOR could serve as an
independent predictor for the poor prognosis of ESCC.
Some controversies and limitations are still not well-
resolved in this meta-analysis. More high-quality world-
wide studies performing a multivariate analysis based on
large sample size will be very helpful for further verifying
and modifying our current findings in the future.
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